Immunologic Factor
Ofatumumab
A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent...
more
Brand Names:
Arzerra; Kesimpta
May Treat:
Mechanism:
CD20-directed Antibody Interactions
More Information:
Medscape
Arzerra (ofatumumab) dosing, indications, interactions, adverse effects, and more.
Viewing results
1 - 10 of 310,000 (0.28 seconds)
-
Oct 15, 2021 ... Ofatumumab Injection (Chronic Lymphocytic Leukemia): learn about side effects, dosage, special precautions, and more on MedlinePlus.
-
Ofatumumab is an anti-CD20 IgG1κ human monoclonal antibody that is being considered by the US Food and Drug Administration and the European Medicines Agency ...
-
Aug 6, 2020 ... Abstract Background Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor ...
-
USES: Ofatumumab is used to treat a certain type of cancer (chronic lymphocytic leukemia - CLL). Ofatumumab belongs to a class of drugs known as monoclonal ...
-
Ofatumumab is an anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and ...
-
A drug used alone or with other drugs to treat certain types of chronic lymphocytic leukemia. It is also being studied in the treatment of other types of cancer ...
-
Feb 1, 2022 ... Ofatumumab injection is used in combination with chlorambucil to treat a type of cancer of the white blood cells called chronic lymphocytic ...
-
A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab ...
-
Aug 28, 2018 ... Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS). The safety and scientific ...
-
Jun 20, 2019 ... Ofatumumab is the first, fully human, anti-CD20 monoclonal antibody in Phase 3 development for multiple sclerosis (MS).